Diebold Martin, Galli Edoardo, Kopf Andreas, Sanderson Nicholas, Callegari Ilaria, Ingelfinger Florian, Núñez Nicolás Gonzalo, Benkert Pascal, Kappos Ludwig, Kuhle Jens, Becher Burkhard, Claassen Manfred, Derfuss Tobias
Multiple Sclerosis Center, Neurologic Clinic and Policlinic, Department of Biomedicine and Research Center for Clinical Neuroimmunology and Neuroscience Basel, University Hospital Basel, University of Basel, Basel, Switzerland.
Institute of Neuropathology, Neurocenter, University Hospital Freiburg, Freiburg, Germany.
Ann Neurol. 2022 May;91(5):676-681. doi: 10.1002/ana.26328. Epub 2022 Mar 4.
Treatment with dimethyl fumarate (DMF) leads to lymphopenia and infectious complications in a subset of patients with multiple sclerosis (MS). Here, we aimed to reveal immune markers of DMF-associated lymphopenia. This prospective observational study longitudinally assessed 31 individuals with MS by single-cell mass cytometry before and after 12 and 48 weeks of DMF therapy. Employing a neural network-based representation learning approach, we identified a CCR4-expressing T helper cell population negatively associated with relevant lymphopenia. CCR4-expressing T helper cells represent a candidate prognostic biomarker for the development of relevant lymphopenia in patients undergoing DMF treatment. ANN NEUROL 2022;91:676-681.
富马酸二甲酯（DMF）治疗会导致一部分多发性硬化症（MS）患者出现淋巴细胞减少和感染并发症。在此，我们旨在揭示与DMF相关淋巴细胞减少的免疫标志物。这项前瞻性观察性研究在DMF治疗12周和48周前后，通过单细胞质谱流式细胞术对31例MS患者进行了纵向评估。采用基于神经网络的表征学习方法，我们鉴定出一个与相关淋巴细胞减少呈负相关的表达CCR4的辅助性T细胞群体。表达CCR4的辅助性T细胞是接受DMF治疗患者发生相关淋巴细胞减少的一个候选预后生物标志物。《神经病学纪事》2022年；91:676 - 681。
